Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation.
Chronic graft-versus-host disease (GVHD) is the major complication in patients surviving > 100 days post-allogeneic bone marrow transplantation and occurs in 30% of pediatric patients. It is most prevalent 1-2 years post-transplant. Treatment involves corticosteroids and other immunosuppressive therapy which may affect growth and increase the likelihood of infectious complications. We report five children with severe corticosteroid-dependent chronic GVHD treated with thalidomide 12-25 mg/kg/day. Response to therapy was based on resolution of symptoms of chronic GVHD and withdrawal of other immunosuppressive therapy. All the children showed clinical response to thalidomide with cessation or diminution in other immunosuppressive medication. Side-effects were minimal and no patient developed peripheral neuropathy. All patients are alive 48-65 months post-transplantation. Thalidomide is a safe and effective drug for the treatment of chronic GVHD in children and may avoid the use of long-term corticosteroid therapy.
Cole
C H
CH
Department of Pediatric Hematology/Oncology, British Columbia Children's Hospital, Vancouver, Canada.
Rogers
P C
PC
Pritchard
S
S
Phillips
G
G
Chan
K W
KW
D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007223:Infant; D008297:Male; D013792:Thalidomide / Q000627:therapeutic use*
D013792:Thalidomide